title: Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy.
abstract: We report on three patients with multiple myeloma who developed drug-induced pneumonitis 1-2(1/2) months following maintenance (post autologous transplantation) chemotherapy with CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) and 6-20 months after exposure to carmustine (BCNU) 300 mg/m(2), used in combination with melphalan 140 mg/m(2), as pre-transplant conditioning regimen. All patients had either a proven (two) or suspected (one) fungal pneumonia and were treated with liposomal amphotericin B. Dyspnea, fever and cough were the prominent clinical symptoms, while air-space disease with ground glass appearance was seen radiographically. Histologic features typical for drug-induced lung injury were detected. All patients had a dramatic, clinical and radiographic response to a brief course of corticosteroids. Although CDEP-induced pneumonitis appears to be a rare complication, its early recognition and prompt treatment, as well as its possible association with preceding fungal infection may have important clinical implications.
authors.affiliation: Department of Medicine, Division of Bone Marrow and Stem Cell Transplantation, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
authors.forename: A
authors.initials: A
authors.lastname: Fassas
authors.forename: I
authors.initials: I
authors.lastname: Gojo
authors.forename: A
authors.initials: A
authors.lastname: Rapoport
authors.forename: M
authors.initials: M
authors.lastname: Cottler-Fox
authors.forename: B
authors.initials: B
authors.lastname: Meisenberg
authors.forename: J C
authors.initials: JC
authors.lastname: Papadimitriou
authors.forename: G
authors.initials: G
authors.lastname: Tricot
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008172:Lung Diseases, Fungal / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy / Q000628:therapy; D011020:Pneumonia, Pneumocystis / Q000139:chemically induced / Q000473:pathology; D013577:Syndrome; D019172:Transplantation Conditioning / Q000009:adverse effects
chemical_list: D005047:Etoposide; D003907:Dexamethasone; D003520:Cyclophosphamide; D002945:Cisplatin; D002330:Carmustine